Cargando…

Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates

BACKGROUND: The contact factor XII (FXII) activates upon contact with a variety of charged surfaces. Activated FXII (FXIIa) activates factor XI, which activates factor IX, resulting in thrombin generation, platelet activation, and fibrin formation. In both in vitro and in vivo rabbit models, compone...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallisch, Michael, Lorentz, Christina U., Lakshmanan, Hari H. S., Johnson, Jennifer, Carris, Marschelle R., Puy, Cristina, Gailani, David, Hinds, Monica T., McCarty, Owen J. T., Gruber, András, Tucker, Erik I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040549/
https://www.ncbi.nlm.nih.gov/pubmed/32110750
http://dx.doi.org/10.1002/rth2.12309
_version_ 1783501012641775616
author Wallisch, Michael
Lorentz, Christina U.
Lakshmanan, Hari H. S.
Johnson, Jennifer
Carris, Marschelle R.
Puy, Cristina
Gailani, David
Hinds, Monica T.
McCarty, Owen J. T.
Gruber, András
Tucker, Erik I.
author_facet Wallisch, Michael
Lorentz, Christina U.
Lakshmanan, Hari H. S.
Johnson, Jennifer
Carris, Marschelle R.
Puy, Cristina
Gailani, David
Hinds, Monica T.
McCarty, Owen J. T.
Gruber, András
Tucker, Erik I.
author_sort Wallisch, Michael
collection PubMed
description BACKGROUND: The contact factor XII (FXII) activates upon contact with a variety of charged surfaces. Activated FXII (FXIIa) activates factor XI, which activates factor IX, resulting in thrombin generation, platelet activation, and fibrin formation. In both in vitro and in vivo rabbit models, components of medical devices, including extracorporeal oxygenators, are known to incite fibrin formation in a FXII‐dependent manner. Since FXII has no known role in hemostasis and its inhibition is therefore likely a safe antithrombotic approach, we investigated whether FXII inhibition also reduces accumulation of platelets in extracorporeal oxygenators. OBJECTIVES: We aimed to determine the effect of FXII inhibition on platelet deposition in perfused extracorporeal membrane oxygenators in nonhuman primates. METHODS: A potent FXII neutralizing monoclonal antibody, 5C12, was administered intravenously to block contact activation in baboons. Extracorporeal membrane oxygenators were temporarily deployed into chronic arteriovenous access shunts. Radiolabeled platelet deposition in oxygenators was quantified in real time using gamma camera imaging. Biochemical assays were performed to characterize the method of action of 5C12. RESULTS: The anti‐FXII monoclonal antibody 5C12 recognized both the alpha and beta forms of human and baboon FXII by binding to the protease‐containing domain, and inhibited FXIIa activity. Administration of 5C12 to baboons reduced platelet deposition and fibrin formation in the extracorporeal membrane oxygenators, in both the presence and absence of systemic low‐dose unfractionated heparin. The antiplatelet dose of 5C12 did not cause measurable increases in template bleeding times in baboons. CONCLUSIONS: FXII represents a possible therapeutic and safe target for reducing platelet deposition and fibrin formation during medical interventions including extracorporeal membrane oxygenation.
format Online
Article
Text
id pubmed-7040549
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70405492020-02-27 Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates Wallisch, Michael Lorentz, Christina U. Lakshmanan, Hari H. S. Johnson, Jennifer Carris, Marschelle R. Puy, Cristina Gailani, David Hinds, Monica T. McCarty, Owen J. T. Gruber, András Tucker, Erik I. Res Pract Thromb Haemost Original Articles: Thrombosis BACKGROUND: The contact factor XII (FXII) activates upon contact with a variety of charged surfaces. Activated FXII (FXIIa) activates factor XI, which activates factor IX, resulting in thrombin generation, platelet activation, and fibrin formation. In both in vitro and in vivo rabbit models, components of medical devices, including extracorporeal oxygenators, are known to incite fibrin formation in a FXII‐dependent manner. Since FXII has no known role in hemostasis and its inhibition is therefore likely a safe antithrombotic approach, we investigated whether FXII inhibition also reduces accumulation of platelets in extracorporeal oxygenators. OBJECTIVES: We aimed to determine the effect of FXII inhibition on platelet deposition in perfused extracorporeal membrane oxygenators in nonhuman primates. METHODS: A potent FXII neutralizing monoclonal antibody, 5C12, was administered intravenously to block contact activation in baboons. Extracorporeal membrane oxygenators were temporarily deployed into chronic arteriovenous access shunts. Radiolabeled platelet deposition in oxygenators was quantified in real time using gamma camera imaging. Biochemical assays were performed to characterize the method of action of 5C12. RESULTS: The anti‐FXII monoclonal antibody 5C12 recognized both the alpha and beta forms of human and baboon FXII by binding to the protease‐containing domain, and inhibited FXIIa activity. Administration of 5C12 to baboons reduced platelet deposition and fibrin formation in the extracorporeal membrane oxygenators, in both the presence and absence of systemic low‐dose unfractionated heparin. The antiplatelet dose of 5C12 did not cause measurable increases in template bleeding times in baboons. CONCLUSIONS: FXII represents a possible therapeutic and safe target for reducing platelet deposition and fibrin formation during medical interventions including extracorporeal membrane oxygenation. John Wiley and Sons Inc. 2020-02-11 /pmc/articles/PMC7040549/ /pubmed/32110750 http://dx.doi.org/10.1002/rth2.12309 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles: Thrombosis
Wallisch, Michael
Lorentz, Christina U.
Lakshmanan, Hari H. S.
Johnson, Jennifer
Carris, Marschelle R.
Puy, Cristina
Gailani, David
Hinds, Monica T.
McCarty, Owen J. T.
Gruber, András
Tucker, Erik I.
Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title_full Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title_fullStr Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title_full_unstemmed Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title_short Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
title_sort antibody inhibition of contact factor xii reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates
topic Original Articles: Thrombosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040549/
https://www.ncbi.nlm.nih.gov/pubmed/32110750
http://dx.doi.org/10.1002/rth2.12309
work_keys_str_mv AT wallischmichael antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT lorentzchristinau antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT lakshmananharihs antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT johnsonjennifer antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT carrismarscheller antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT puycristina antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT gailanidavid antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT hindsmonicat antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT mccartyowenjt antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT gruberandras antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates
AT tuckereriki antibodyinhibitionofcontactfactorxiireducesplateletdepositioninamodelofextracorporealmembraneoxygenatorperfusioninnonhumanprimates